Using Your Immune System to Defeat Cancer
Innovative Immunotherapies
At Agenus, we’re reimagining cancer treatment by activating the immune system to do what it was meant to do—recognize and eliminate disease. Our comprehensive portfolio of immunotherapies works across the cancer immunity cycle, with the goal of reducing reliance on chemotherapy, radiation, and invasive surgeries—helping more patients live longer, fuller lives.
Learn how our science is changing what’s possible
“30 years ago, we envisioned a future where the immune system could be harnessed to cure cancer. That vision remains our driving force today—science-led, patient-focused, and unwavering in our mission to transform outcomes.”
BOT + BAL
Bringing the Power of Immunotherapy to More Patients
Botensilimab (BOT) plus Balstilimab (BAL) represents the next generation of immunotherapy, designed to help more patients benefit from the body’s own defenses against cancer.
Neoadjuvant Botensilimab (BOT) plus Balstilimab (BAL) in Resectable Stage III Microsatelitte Stable (MSS) Colorectal Cancer
BAL, balstilimab; BOT, botensilimab; MSS, microsatellite stable, CR, Complete Response. 1. Kasi P, et al. Oral presentation at the ESMO Gastrointestinal Cancers Congress. Munich, Germany. 2024. Presentation #743. 2. Chalabi M, et al. Oral presentation as AACR. Chicago, IL, USA. 2025. Abstract #CT130.
Neoadjuvant Botensilimab (BOT) plus Balstilimab (BAL) in Merkel Cell Carcinoma of the Left Elbow
ClinicalTrials.gov Identifier: NCT06279130. BAL, balstilimab; BOT, botensilimab; MCC, Merkel cell carcinoma; MPR, major pathologic response; pMMR, mismatch repair proficient; PR, pathologic response. Chalabi M, et al. Oral presentation as AACR 2025. Chicago, IL, USA. 2025. Abstract #CT130.
Neoadjuvant Botensilimab (BOT) plus Balstilimab (BAL) in Undifferentiated Pleomorphic Sarcoma of the Upper Leg
ClinicalTrials.gov Identifier: NCT06279130. BAL, balstilimab; BOT, botensilimab; MPR, major pathologic response; pMMR, mismatch repair proficient; PR, pathologic response; UPS, undifferentiated pleiomorfsarcoma. Chalabi M, et al. Oral presentation as AACR 2025. Chicago, IL, USA. 2025. Abstract #CT130.
In the News
Get answers about clinical trials, patient access, and more
Acceleration Through Partnerships
Agenus advances its mission through strategic collaborations that expand the reach and impact of our science. While we retain ownership of most programs, select partnerships bring global development expertise, capital, and technology that accelerate discovery, strengthen our pipeline, and improve patient outcomes.
By the Numbers
Our vision is to broaden the number of patients who benefit from immunotherapy by advancing combination approaches that draw on our diverse portfolio of antibody therapeutics, access to adoptive cell therapies, and adjuvant and vaccine platforms.
